What changed: Spinal cord tumours (intramedullary and intradural)
Every dated change on the records linked to Spinal cord tumours (intramedullary and intradural), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Guideline1Milestone5This record1
September 2026 · 1
2021 · 3
- 2021GuidelineSpinal cord tumours (intramedullary and intradural)Guideline FDA label 2021: Von Hippel-Lindau haemangioblastoma not needing immediate surgery
Belzutifan, the HIF-2 alpha inhibitor approved for VHL-associated central nervous system haemangioblastomas, with surveillance imaging.
- 2021MilestoneBelzutifanBelzutifan approved for von Hippel-Lindau tumours including CNS haemangioblastomas
A milestone in how this cancer is treated.
- 2021MilestoneSpinal cord tumours (intramedullary and intradural)WHO 2021 lists spinal ependymoma, MYCN-amplified, and regrades myxopapillary ependymoma to grade 2
A milestone in how this cancer is treated.